Low-dose methotrexate adverse reaction risk in renal impairment: pharmacovigilance and physiological pharmacokinetic model assessment
LD-MTX confers increased adverse reaction risks in renal impairment, notably from CKD stage 2 or higher, necessitating dose adjustments and vigilant monitoring.
Authors
- Deshi Dong (ORCID: https://orcid.org/0000-0003-3266-4314)
- Xin Wang (ORCID: https://orcid.org/0000-0002-7592-7789)
- Shilei Yang (ORCID: https://orcid.org/0000-0001-9468-7488)
- Yaolei Zhang (ORCID: https://orcid.org/0000-0003-2131-0254)
- Yanna Zhu (ORCID: https://orcid.org/0000-0003-4160-3695)
- Jianling Li (ORCID: https://orcid.org/0000-0002-6381-1957)
- Lichang Zhang
- Shilei Gao (ORCID: https://orcid.org/0009-0006-7130-4652)
Institutions
- Dalian Medical University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fphar.2025.1703557
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00